APA (7th ed.) Citation

HH, A., RH, S., W, W., & WW, I. (2026). The Neuroprotective Effects of Agomelatine in a 3‑Nitropropionic Acid-Induced Rat Model of Huntington's Disease via Brain-Derived Neurotrophic Factor (BDNF)/tropomyosin-Related Kinase Receptor Type B (TrKB)/Phosphoinositide 3‑Kinase (PI3K)/Protein Kinase B (AKT) Activation and Rho-Associated Protein Kinase 1 (ROCK1) Pathway Inhibition. ACS pharmacology & translational science, 9(2), 414. https://doi.org/10.1021/acsptsci.5c00721

Chicago Style (17th ed.) Citation

HH, Abouzaid, Sayed RH, Wadie W, and Ibrahim WW. "The Neuroprotective Effects of Agomelatine in a 3‑Nitropropionic Acid-Induced Rat Model of Huntington's Disease via Brain-Derived Neurotrophic Factor (BDNF)/tropomyosin-Related Kinase Receptor Type B (TrKB)/Phosphoinositide 3‑Kinase (PI3K)/Protein Kinase B (AKT) Activation and Rho-Associated Protein Kinase 1 (ROCK1) Pathway Inhibition." ACS Pharmacology & Translational Science 9, no. 2 (2026): 414. https://doi.org/10.1021/acsptsci.5c00721.

MLA (9th ed.) Citation

HH, Abouzaid, et al. "The Neuroprotective Effects of Agomelatine in a 3‑Nitropropionic Acid-Induced Rat Model of Huntington's Disease via Brain-Derived Neurotrophic Factor (BDNF)/tropomyosin-Related Kinase Receptor Type B (TrKB)/Phosphoinositide 3‑Kinase (PI3K)/Protein Kinase B (AKT) Activation and Rho-Associated Protein Kinase 1 (ROCK1) Pathway Inhibition." ACS Pharmacology & Translational Science, vol. 9, no. 2, 2026, p. 414, https://doi.org/10.1021/acsptsci.5c00721.